3.80Open3.80Pre Close0 Volume25 Open Interest12.50Strike Price0.00Turnover188.96%IV7.05%PremiumMay 16, 2025Expiry Date3.14Intrinsic Value100Multiplier6DDays to Expiry0.66Extrinsic Value100Contract SizeAmericanOptions Type-0.8474Delta0.1009Gamma2.84Leverage Ratio-0.0412Theta-0.0017Rho-2.40Eff Leverage0.0029Vega
Stoke Therapeutics Stock Discussion
Stoke Therapeutics Taps Former Vertex COO as Interim CEO Amid Breakthrough Drug Progress
Stoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet Syndrome
No comment yet